Preview

Российский неврологический журнал

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Прогрессирующая наружная офтальмоплегия

https://doi.org/10.30629/2658-7947-2019-24-6-4-13

Полный текст:

Аннотация

Прогрессирующая  наружная  офтальмоплегия  (ПНО) характеризуется  прогрессирующим  билатеральным птозом и нарушением подвижности глазных яблок в горизонтальном и вертикальном направлениях и представляет собой характерный симптом многих митохондриальных  заболеваний, а не отдельную нозологическую форму. ПНО часто возникает совместно с другими системными проявлениями митохондриальной дисфункции. Правильная и ранняя диагностика ПНО первостепенна для оптимального ведения данных пациентов. В статье представлен обзор последних данных по этиологии, спектру клинических проявлений, дифференциальному диагнозу, методам диагностики и лечебным опциям для изолированной хронической ПНО и других ПНО-ассоциированных митохондриальных синдромов.

Об авторах

Е. В. Яковенко
Научный центр неврологии
Россия

Яковенко Елена Владимировна — аспирант нейрогенетического  отделения/

Москва.



Е. Ю. Федотова
Научный центр неврологии
Россия

Москва.



С. Н. Иллариошкин
Научный центр неврологии
Россия

Москва.



Список литературы

1. Von Graefe A. Symptomen lehreder Augenmuskellahmungen. Berlin: Peters, 1867.

2. Kearns T.P., Sayre G.P. Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60(2):280-9.

3. Drachman D.A. Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia. Arch Neurol. 1968;18(6):654-74.

4. Reske-Nielsen E., Lou H.C., Lowes M. Progressive external ophthalmoplegia. Evidence for a generalised mitochondrial disease with a defect in pyruvate metabolism. Acta Ophthalmol (Copenh). 1976;54(5):553-73.

5. Olson W., Engel W.K., Walsh G.O., Einaugler R. Oculocraniosomatic neuromuscular disease with ragged-redfibers. Arch Neurol. 1972;26(3):193-211.

6. Elliott H.R., Samuels D.C., Eden J.A., Relton C.L., Chinnery P.F. Pathogenicmitochondrial DNA mutations are common in the general population. Am J HumGenet.2008;83(2):254-60.

7. Schaefer A.M., McFarland R., Blakely E.L., et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63:35-9.

8. Petty R.K., Harding A.E., Morgan-Hughes J.A. The clinical features of mitochondrial myopathy. Brain. 1986;109(5):915-38.

9. Bucelli R.C., Lee M.S., McClelland C.M. Chronic Progressive External Ophthalmoplegia in the Absence of Ptosis. J Neuroophthalmol. 2016 Sep;36(3):27-4.

10. Shorr N., Christenbury J.D., Goldberg R.A. Management of ptosis in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg. 1987;3(3):141-5.

11. Hart P.E., De Vivo D.C., Schapira A.H. Clinical features of the mitochondrial encephalomyopathies. In: Shapira A.H., DiMauro S., eds. Mitochondrial Disorders in Neurology 2. Woburn: Butterworth-Heineman; 2002:35-68.

12. Yu Wai Man C.Y., Smith T., Chinnery P.F., Turnbull D.M., Griffiths P. G. Assessment of visual function in chronic progressive external ophthalmoplegia. Eye (Lond). 2006;20(5):564-8.

13. Pfeffer G., Sirrs S., Wade N.K., Mezei M.M. Multisystem disorder in late-onset chronic progressive external ophthalmoplegia. Can J Neurol Sci. 2011;38(1):119-23.

14. Phadke M., Lokeshwar M.R., Bhutada S., Tampi C., Saxena R., Kohli S., Shah K.N. KearnsSayre Syndrome — case report with review of literature. Indian JPediatr. 2012 May;79(5):650-4.

15. Reichmann H., Degoul F., Gold R., Meurers B., Ketelsen U.P., Hartmann J., Marsac C., Lestienne P. Histological, enzymatic and mitochondrial DNA studies in patients with Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia. Eur Neurol. 1991;31(2):108-13.

16. Tsang S.H., Aycinena A.R.P., Sharma T. Mitochondrial Disorder: Kearns-Sayre Syndrome. Adv. Exp. Med. Biol. 2018;1085:161-162.

17. Saldana-Martinez A., Munoz M.L., Perez-Ramirez G., Montiel-Sosa J.F., Montoya J., Emperador S., et al. Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: Identification of deletions and variants. Gene. 2019 Mar 10;688:171-181.

18. Miller N.R., Walsh F.B., Hoyt W.F. Walsh and Hoyt’s clinical neuroophthalmology. Vol. 1. 6th ed. Philadelphia, Pa; London: Lippincott Williams & Wilkins; 2005.

19. Mullie M.A., Harding A.E., Petty R.K., Ikeda H., Morgan-Hughes J.A., Sanders M.D. The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 1985;103(12):1825-30.

20. Young T.J., Shah A.K., Lee M.H., Hayes D.L. Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol. 2005;28(5):454-7.

21. Chu B.C., Terae S., Takahashi C., Kikuchi Y, Miyasaka K., Abe S. et al. MRI of the brain in the Kearns-Sayre syndrome: report of four cases and a review. Neuroradiology. 1999;41(10):759-64.

22. Hanisch F., Kornhuber M., Alston C.L., Taylor R.W., Deschauer M., Zierz S. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry. 2015;86(6):630-4.

23. El-Hattab A.W., Adesina A.M., Jones J., Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol GenetMetab. 2015;116(1-2):4-12.

24. Hirano M., Pavlakis S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol. 1994;9(1):4-13.

25. Yu-Wai-Man P., Griffiths P.G., Gorman G.S., et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 3):771-86.

26. Liskova P., Ulmanova O., Tesina P., et al. Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder. Acta Ophthalmol. 2013;91(3):225-31.

27. Amati-Bonneau P., Valentino M.L., Reynier P. et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131(Pt 2):338-51.

28. Lee A.G., Brazis P.W. Chronic progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2002;2(5):413-7.

29. Liu G.T., Volpe N.J., Galetta S.L. Neuro-Ophthalmology: Diagnosis and Management. 2nd ed. Philadelphia, PA: Elsevier (2010).

30. Okamoto K., Ito J., Tokiguchi S., Furusawa T. Atrophy of bilateral extraocular muscles — CT and clinical features of seven patients. J Neuro-Ophthalmol. 1996;16(4):286-8.

31. Ortube M.C., Bhola R., Demer J.L. Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: specific diagnostic findings. J Aapos. 2006;10(5):414-8.

32. Mitochondrial Medicine Society’s Committee on Haas R.H., Parikh S. et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94(1):16-37.

33. Pfeffer G., Chinnery P.F. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4-16.

34. Milone M., Wong L.J. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110(1-2):35-41.

35. Krendel D.A., Sanders D.B., Massey J.M. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve. 1987;10(4):299-302.

36. Trivedi M., Goldstein A., Arora G. Prophylactic pacemaker placement at first signs of conduction disease in Kearns-Sayre syndrome. Cardiol Young. 2018 Dec;28(12):1487-1488.

37. Shemesh A., Margolin E. Kearns Sayre Syndrome. 2019 Jun 3. StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan.

38. Nguyen M.T.B., Micieli J., Margolin E. Teaching NeuroImages: Kearns-Sayre syndrome. Neurology. 2019 Jan 29;92(5):e519-e520.

39. Berio A., Piazzi A., Traverso C.E. Kearns-Sayre syndrome with facial and white matter extensive involvement: a (mitochondrial and nuclear gene related?) neurocristopathy? Pediatr Med Chir. 2017 Dec 15;39(4):169.

40. Moraes C.T., DiMauro S., Zeviani M., et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;320(20):1293-9.

41. Lopez-Gallardo E., Lopez-Perez M.J., Montoya J., Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion. 2009;9(5):314-7.

42. Mancuso M., Orsucci D., Angelini C., et al. Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol. 2015;262(5):1301-9.

43. Schon E.A., Rizzuto R., Moraes C.T. et al. (1989). A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science. 244:346-349.

44. Lamantea E., Tiranti V, Bordoni A. et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52(2):211-9.

45. Kaukonen J., Juselius J.K., Tiranti V et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289(5480):782-5.

46. Spelbrink J.N., Li F.Y., Tiranti V., et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet. 2001;28(3):223-31.

47. Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., Suomalainen A. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet. 2009;85(2):290-5.

48. Ronchi D., Di Fonzo A., Lin W., et al. Mutations in DNA2 link progressive myopathy to mitochondrial DNA instability. Am J Hum Genet. 2013;92(2):293-300.

49. Hudson G., Amati-Bonneau P., Blakely E.L., et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain. 2008;131(Pt 2):329-37.

50. Hirano M., DiMauro S. ANT1, twinkle, POLG, and TP — new genes open our eyes to ophthalmoplegia. Neurology. 2001;57(12):2163-5.

51. Gonzalez-Vioque E., Blazquez A., Fernandez-Moreira D., et al. Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population. Arch Neurol. 2006;63(1):107-11.

52. HorgaA., Pitceathly R.D., Blake J.C., et al. Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia. Brain. 2014;137(Pt 12):3200-12.

53. Pfeffer G., Gorman G.S., Griffin H., et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain. 2014 May;137(Pt 5):1323-36.

54. Lamantea E., Tiranti V., Bordoni A., et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52(2):211-9.

55. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999;283(5402):689-92.

56. Kornblum C., Nicholls T.J., Haack T.B., et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet. 2013;45(2):214-9.

57. Reyes A., Melchionda L., Nasca A., et al. RNASEH1 mutations impair mtDNA replication and cause adult-onset mitochondrial encephalomyopathy. Am J Hum Genet. 2015;97(1):186-93.

58. McClelland C., Manousakis G., Lee M.S. Progressive External Ophthalmoplegia. CurrNeurolNeurosciRep. 2016 Jun;16(6):53.

59. Sundaram C., Meena A.K., Uppin M.S., et al. Contribution of muscle biopsy and genetics to the diagnosis of chronic progressive external opthalmoplegia of mitochondrial origin. J Clin Neurosci. 2011;18(4):535-8.

60. Schaefer A.M., Blakely E.L., Griffiths P.G., Turnbull D.M., Tay¬lor R.W. Ophthalmoplegia due to mitochondrial DNA disease: the need for genetic diagnosis. Muscle Nerve. 2005;32(1):104-7.

61. Pfeffer G., Waters P. J., Maguire J., Vallance H.D., Wong V A., Mezei M.M. Levator palpebrae biopsy and diagnosis of progressive external ophthalmoplegia. Can J Neurol Sci. 2012;39(4):520-4.

62. Wong L.J. Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion. 2013;13(4):379-87.

63. Gonzalez-Moron D., Bueri J., Kauffman M.A. Progressive ex¬ternal ophthalmoplegia (PEO) due to a mutation in the C10orf2 (PEO1) gene mimicking a myasthenic crisis. BMJ Case Rep. 2013;2013.

64. Behbehani R., Sharfuddin K., Anim J.T. Mitochondrial ophthal-moplegia with fatigable weakness and elevated acetylcholine re-ceptor antibody. JNeuroophthalmol. 2007;27(1):41-4.

65. Wong K.T., Dick D., Anderson J.R. Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1996; 6(3):163-6.

66. Yum K., Wang E.T., Kalsotra A. Myotonic dystrophy: disease re¬peat range, penetrance, age of onset, and relationship between re¬peat size and phenotypes. Curr Opin Genet Dev. 2017; 44:30-7.

67. Poulton J., Harley H.G., Dasmahapatra J., Brown G.K., Pot¬ter C.G., Sykes B. Mitochondrial DNA does not appear to influence the congenital onset type of myotonic dystrophy. J Med Genet. 1995;32(9):732-5.

68. Hamedani A.G., Gold D.R. Eyelid Dysfunction in Neurodegen-erative, Neurogenetic,and Neurometabolic Disease. Front Neu¬rol. 2017; Jul 18;8:329.

69. Kiferle L., Orsucci D., Mancuso M., Lo Gerfo A., Petrozzi L., Siciliano G., et al. Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: a case report and an update on the state of the art. Neurosci Lett. 2013; 556:1-4.

70. Amboni M., Pellecchia M.T., Cozzolino A., Picillo M., Vitale C., Barone P., et al. Cerebellar and pyramidal dysfunctions, palpe¬bral ptosis and weakness as the presenting symptoms of PARK-2. Mov Disord. 2009;24(2):303-5.

71. Zuhlke C., Mikat B., Timmann D., Wieczorek D., Gillessen-Kaesbach G., Burk K. Spinocerebellar ataxia 28: novel AFG3L2 mutation in a German family with young onset, slow progression and saccadic slowing. Cerebellum Ataxias. 2015;2:19.

72. Gorman G.S., Pfeffer G., Griffin H., Blakely E.L., Kurzawa-Akanbi M., Gabriel J., et al. Clonal expansion of secondary mito¬chondrial DNA deletions associated with spinocerebellar ataxia type 28. JAMA Neurol. 2015;72(1):106-11.

73. Kersten R.C., de Conciliis C., Kulwin D.R. Acquired ptosis in the young and middle-aged adult population. Ophthalmology. 1995;102:924-8.

74. Verhulst S., Smet H., De Wilde F., Tassignon M.J. Levator apo-neurosis dehiscence in a patient treated with botulinum toxin for blepharospasms and eyelid apraxia. Bull Soc Belge Ophthalmol. 1994;252:51-3.

75. Ng J., Papandreou A., Jeales S.J., Kurian M.A. Monoamine neurotransmitter disorders — clinical advances and future direc-tions. Nat Rev Neurol. 2015;11:567-84.

76. Pineles S.L., Demer J.L., Holland G.N., Ransome S.S., Bonelli L., Velez F.G. External ophthalmoplegia in human immunode¬ficiency virus-infected patients receiving antiretroviral therapy. Jaapos. 2012;16(6):529-33.

77. Pfeffer G., Cote H.C., Montaner J.S., Li C.C., Jitratkosol M., Mezei M.M. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HlV therapy. Neurology. 2009;73(1):71-2.

78. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin thera¬py induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94-102.

79. Fraunfelder F.W., Richards A.B. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reduc¬tase inhibitor use. Ophthalmology. 2008;115(12):2282-5.

80. Lapid O., Lapid-Gortzak R., Barr J., Rosenberg L. Eyelid crutches for ptosis: a forgotten solution. Plast Reconstr Surg. 2000;106(5):1213-4.

81. de Castro F.A., Cruz A.A., Sobreira C.F. Brow motil¬ity in mitochondrial myopathy. Ophthal Plast Reconstr Surg. 2010;26(6):416-9.

82. Wallace D.K., Sprunger D.T., Helveston E.M., Ellis F.D. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997;104(4):695-700.

83. Finsterer J., Haberler C., Schmiedel J. Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol. 2005;28:148-9.

84. Parikh S., Goldstein A., Koenig M.K., Scaglia F., Enns G.M., Saneto R. et al. Diagnosis and management of mitochondrial dis¬ease: a consensus statement from the Mitochondrial Medicine Society. Genet Med: Off J Am Coll Med Genet. 2015;17:689-701.

85. Muraresku C.C., McCormick E.M., Falk M.J. Mitochondrial Disease: Advances in clinical diagnosis, management, therapeu¬tic development, and preventative strategies. Curr Genet Med Rep. 2018 Jun;6(2):62-72.

86. Sadun A.A., Chicani C.F., Ross-Cisneros F.N., Barboni P., Thoolen M., Shrader W.D. et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neu¬ropathy. Arch Neurol. 2012 Mar;69(3):331-8.


Для цитирования:


Яковенко Е.В., Федотова Е.Ю., Иллариошкин С.Н. Прогрессирующая наружная офтальмоплегия. Российский неврологический журнал. 2019;24(6):4-13. https://doi.org/10.30629/2658-7947-2019-24-6-4-13

For citation:


Iakovenko E.V., Fedotova E.Yu., Illarioshkin S.N. Progressive external ophthalmoplegia. Russian neurological journal. 2019;24(6):4-13. (In Russ.) https://doi.org/10.30629/2658-7947-2019-24-6-4-13

Просмотров: 286


ISSN 2658-7947 (Print)
ISSN 2686-7192 (Online)